Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Vector Science and Therapeutics's EV-to-FCF or its related term are showing as below:
TSXV:PAIN'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.67 Med: 0 Max: 0
Current: -2.67
TSXV:PAIN's EV-to-FCF is ranked worse than 100% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.21
vs TSXV:PAIN: -2.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vector Science and Therapeutics (TSXV:PAIN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vector Science and Therapeutics's PE Ratio (TTM) for today is calculated as:
Vector Science and Therapeutics's share price for today is C$1.55.
Vector Science and Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.312.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vector Science and Therapeutics EV-to-FCF Related Terms
Vector Science and Therapeutics EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vector Science and Therapeutics EV-to-FCF Chart
Vector Science and Therapeutics Annual Data
Trend
Aug24
Aug25
EV-to-FCF
0.00
0.00
Vector Science and Therapeutics Quarterly Data
Aug24
Nov24
Aug25
Nov25
Feb26
EV-to-FCF
0.00
0.00
0.00
0.00
0.00
TSXV:PAIN vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Vector Science and Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vector Science and Therapeutics EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vector Science and Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vector Science and Therapeutics's EV-to-FCF falls into.
Vector Science and Therapeutics's current Enterprise Value is C$7.30 Mil.
Vector Science and Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vector Science and Therapeutics (TSXV:PAIN) has a EV-to-FCF of -2.53 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vector Science and Therapeutics and its competitors. According to the industry distribution chart, Vector Science and Therapeutics ranks #999999 out of 414 companies in the Medical Devices & Instruments industry.
Is Vector Science and Therapeutics' EV-to-FCF too high?
Vector Science and Therapeutics' current EV-to-FCF is -2.53. Based on the distribution chart, Vector Science and Therapeutics ranks #999999 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vector Science and Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vector Science and Therapeutics ranks #999999 out of 414 companies for EV-to-FCF. This places Vector Science and Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 23.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.21, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vector Science and Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vector Science and Therapeutics's current EV-to-FCF is -2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current EV-to-FCF of -2.53. The current EV-to-FCF is -2.53. Vector Science and Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current EV-to-FCF is -2.53 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vector Science and Therapeutics Business Description
Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
14GF Score
Get the complete analysis for TSXV:PAIN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PAIN has been successfully added to your 
